Skip Nav Destination
Issues
1 March 2014
-
Cover Image
Cover Image
The cover image shows immunofluorescence staining of normal breast tissue obtained from surgical specimens. The staining was performed with anti-Afadin (red channel), anti–E-cadherin (green channel), and DAPI (blue channel). The staining pattern reveals Afadin staining that is largely membrane restricted and excluded from nuclei. By contrast, in surgical specimens obtained from invasive breast carcinoma, Afadin shows a predominately nuclear expression pattern with near complete loss of membrane localization. For more information, see the article by Elloul and colleagues, beginning on page 464 in this issue. In this study, the authors conclude that nuclear translocation of Afadin, mediated by the PI3K and Akt pathway, is associated with enhanced breast cancer cell migration and in turn, tumor progression. - PDF Icon PDF LinkTable of Contents
ISSN 1541-7786
EISSN 1557-3125
Molecular Cancer Research
Table of Contents
Highlights
Review
Cell Cycle and Senescence
Cell Death and Survival
Chromatin, Gene, and RNA Regulation
DNA Damage and Repair
Genomics
NF-κB Activation-Induced Anti-apoptosis Renders HER2-Positive Cells Drug Resistant and Accelerates Tumor Growth
Shannon T. Bailey; Penelope L. Miron; Yoon J. Choi; Bose Kochupurakkal; Gautam Maulik; Scott. J. Rodig; Ruiyang Tian; Kathleen M. Foley; Teresa Bowman; Alexander Miron; Myles Brown; J. Dirk. Iglehart; Debajit K. Biswas
Oncogenes and Tumor Suppressors
Signal Transduction
Journal Archive
Molecular Cancer Research
(2002-Present; volumes 1-current)Published monthly since November, 2002.
(ISSN 0008-5472)
Cell Growth & Differentiation
(1990-2002; volumes 1-13)Published monthly 1990- September, 2002.
(ISSN 1044-9523)
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.